drugset / Trial / NCT00701181

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema

NCT00701181

Phase 2 Terminated 184 enrolled Quark Pharmaceuticals Pfizer · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the effectiveness of study drug in improving visual acuity compared to laser treatment in the patients with diabetic macular edema

Timeline

Start
2008-06
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04523655 Small interfering RNA (siRNA) 0.4 mg Intravitreal
Subject PF-04523655 Small interfering RNA (siRNA) 1 mg Intravitreal
Subject PF-04523655 Small interfering RNA (siRNA) 3 mg Intravitreal